Novavax Inc
NASDAQ:NVAX

Watchlist Manager
Novavax Inc Logo
Novavax Inc
NASDAQ:NVAX
Watchlist
Price: 9.32 USD 10.04%
Market Cap: 1.5B USD
Have any thoughts about
Novavax Inc?
Write Note

Intrinsic Value

The intrinsic value of one NVAX stock under the Base Case scenario is 7.4 USD. Compared to the current market price of 9.32 USD, Novavax Inc is Overvalued by 21%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NVAX Intrinsic Value
7.4 USD
Overvaluation 21%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Novavax Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NVAX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NVAX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Novavax Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Novavax Inc

Provide an overview of the primary business activities
of Novavax Inc.

What unique competitive advantages
does Novavax Inc hold over its rivals?

What risks and challenges
does Novavax Inc face in the near future?

Has there been any significant insider trading activity
in Novavax Inc recently?

Summarize the latest earnings call
of Novavax Inc.

What significant events have occurred
in Novavax Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Novavax Inc.

Provide P/S
for Novavax Inc.

Provide P/E
for Novavax Inc.

Provide P/OCF
for Novavax Inc.

Provide P/FCFE
for Novavax Inc.

Provide P/B
for Novavax Inc.

Provide EV/S
for Novavax Inc.

Provide EV/GP
for Novavax Inc.

Provide EV/EBITDA
for Novavax Inc.

Provide EV/EBIT
for Novavax Inc.

Provide EV/OCF
for Novavax Inc.

Provide EV/FCFF
for Novavax Inc.

Provide EV/IC
for Novavax Inc.

Show me price targets
for Novavax Inc made by professional analysts.

What are the Revenue projections
for Novavax Inc?

How accurate were the past Revenue estimates
for Novavax Inc?

What are the Net Income projections
for Novavax Inc?

How accurate were the past Net Income estimates
for Novavax Inc?

What are the EPS projections
for Novavax Inc?

How accurate were the past EPS estimates
for Novavax Inc?

What are the EBIT projections
for Novavax Inc?

How accurate were the past EBIT estimates
for Novavax Inc?

Compare the revenue forecasts
for Novavax Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Novavax Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Novavax Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Novavax Inc compared to its peers.

Compare the P/E ratios
of Novavax Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Novavax Inc with its peers.

Analyze the financial leverage
of Novavax Inc compared to its main competitors.

Show all profitability ratios
for Novavax Inc.

Provide ROE
for Novavax Inc.

Provide ROA
for Novavax Inc.

Provide ROIC
for Novavax Inc.

Provide ROCE
for Novavax Inc.

Provide Gross Margin
for Novavax Inc.

Provide Operating Margin
for Novavax Inc.

Provide Net Margin
for Novavax Inc.

Provide FCF Margin
for Novavax Inc.

Show all solvency ratios
for Novavax Inc.

Provide D/E Ratio
for Novavax Inc.

Provide D/A Ratio
for Novavax Inc.

Provide Interest Coverage Ratio
for Novavax Inc.

Provide Altman Z-Score Ratio
for Novavax Inc.

Provide Quick Ratio
for Novavax Inc.

Provide Current Ratio
for Novavax Inc.

Provide Cash Ratio
for Novavax Inc.

What is the historical Revenue growth
over the last 5 years for Novavax Inc?

What is the historical Net Income growth
over the last 5 years for Novavax Inc?

What is the current Free Cash Flow
of Novavax Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Novavax Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Novavax Inc

Current Assets 1.1B
Cash & Short-Term Investments 909.5m
Receivables 95m
Other Current Assets 99.2m
Non-Current Assets 608.8m
PP&E 451.5m
Intangibles 126.8m
Other Non-Current Assets 30.5m
Current Liabilities 1.2B
Accounts Payable 57.5m
Accrued Liabilities 218.7m
Other Current Liabilities 904.8m
Non-Current Liabilities 1.1B
Long-Term Debt 223.6m
Other Non-Current Liabilities 834.3m
Efficiency

Earnings Waterfall
Novavax Inc

Revenue
885.2m USD
Cost of Revenue
-320.5m USD
Gross Profit
564.6m USD
Operating Expenses
-854.7m USD
Operating Income
-290m USD
Other Expenses
5.2m USD
Net Income
-284.9m USD

Free Cash Flow Analysis
Novavax Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

NVAX Profitability Score
Profitability Due Diligence

Novavax Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Exceptional ROE
ROE is Increasing
42/100
Profitability
Score

Novavax Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

NVAX Solvency Score
Solvency Due Diligence

Novavax Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Short-Term Solvency
Long-Term Solvency
40/100
Solvency
Score

Novavax Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NVAX Price Targets Summary
Novavax Inc

Wall Street analysts forecast NVAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NVAX is 17.75 USD with a low forecast of 9.09 USD and a high forecast of 26.25 USD.

Lowest
Price Target
9.09 USD
2% Downside
Average
Price Target
17.75 USD
90% Upside
Highest
Price Target
26.25 USD
182% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NVAX?

Click here to dive deeper.

Dividends

Novavax Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for NVAX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

NVAX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

NVAX News

Other Videos

Profile

Novavax Inc Logo
Novavax Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.5B USD

Dividend Yield

0%

Description

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 1,541 full-time employees. The firm promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

Contact

MARYLAND
Gaithersburg
21 Firstfield Road
+12402682000.0
www.novavax.com

IPO

1973-05-16

Employees

1 541

Officers

President, CEO & Director
Mr. John Charles Jacobs M.B.A.
President & COO
Mr. John Joseph Trizzino B.S., M.B.A.
Executive VP, CFO & Treasurer
Mr. James Patrick Kelly C.F.A.
Executive VP, Chief Legal Officer & Corporate Secretary
Mr. Mark Casey
Executive VP & COO
Mr. Richard P. Crowley
Senior VP, Chief Medical Officer and Interim Head of R&D
Dr. Robert Walker M.D.
Show More
Senior VP, Deputy General Counsel & Chief Compliance Officer
Mr. Troy Morgan Esq., J.D.
Associate Director of Investor & Public Relations
Ms. Erika S. Trahan
Executive VP & Chief Human Resources Officer
Mr. Ian J. Watkins
Executive VP and Chief Corporate Affairs & Advocacy Officer
Ms. Silvia Taylor M.B.A.
Show Less

See Also

Discover More
What is the Intrinsic Value of one NVAX stock?

The intrinsic value of one NVAX stock under the Base Case scenario is 7.4 USD.

Is NVAX stock undervalued or overvalued?

Compared to the current market price of 9.32 USD, Novavax Inc is Overvalued by 21%.

Back to Top